A Study to Evaluate Subjects With Turner Syndrome Treated With Growth Hormone

NCT00097552 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1696

Last updated 2012-11-14

No results posted yet for this study

Summary

This study is a multicenter, open-label, observational, postmarketing surveillance study of Genentech growth hormone (GH) products in the treatment of girls with Turner syndrome in the United States and Canada.

Conditions

  • Turner Syndrome

Sponsors & Collaborators

  • Genentech, Inc.

    lead INDUSTRY

Principal Investigators

  • Barbara Lippe, M.D. · Genentech, Inc.

Eligibility

Max Age
17 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-05-31
Primary Completion
2010-07-31
Completion
2010-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00097552 on ClinicalTrials.gov